Traws Pharma, Inc. (TRAW) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

gentlemen, thank you for standing by. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a question and answer session. To ask a question at that time, please press star followed by one on your touchtone phone. If anyone has difficulty hearing the conference, please press star zero for operator assistance. As a reminder, I would now like to turn the call over to Science Advisors. Thank you, Operator, and welcome everyone to Trust Pharma's full year 2025 financial results and business update conference call. This afternoon, TRAS issued a press release reporting its 2025 financial results and provided a business update. If you have not yet seen this press release, it is available in the investor relations section of the company's website. Following my introduction, we'll hear from TRAS Chief Executive Officer, Dr. Ian Dukes, and Chief Financial Officer, Charles Parker. Before we begin, I would like to remind everyone that statements made during this conference call will include forward-looking statements under the Safe Harbor provisions of the Private Securities Litigation Form Act of 1995, which involved risks and uncertainties that can cause actual results to differ materially. Forward-looking statements speak only as of the date they are made, as the underlying facts and circumstances may change. Except as required by law, TROS disclaims any obligation to update these forward-looking statements to reflect future information, events, or circumstances. For more information on forward-looking statements, please review the disclaimer in this morning's press release and the risk factors in the company's SEC filings. With that, I will now turn the call over to Trous' CEO, Dr. Ian Dukes. Thanks, John, and thanks ...